Quotient Ltd. (NASDAQ:QTNT) shares traded down 3.6% during trading on Wednesday . The company traded as low as $7.13 and last traded at $7.50, with a volume of 52,734 shares trading hands. The stock had previously closed at $7.78.

A number of research analysts recently commented on the company. Jefferies Group restated a “buy” rating and issued a $28.00 target price on shares of Quotient in a research note on Wednesday, June 1st. Zacks Investment Research lowered Quotient from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 13th.

The stock has a 50-day moving average of $9.29 and a 200-day moving average of $10.18. The company’s market capitalization is $107.82 million.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings data on Monday, May 23rd. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.18. The business had revenue of $5.05 million for the quarter. Equities research analysts anticipate that Quotient Ltd. will post ($2.02) EPS for the current fiscal year.

In related news, President Jeremy Stackawitz sold 15,000 shares of Quotient stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the completion of the sale, the president now owns 127,741 shares of the company’s stock, valued at $1,277,410. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen Unger sold 8,516 shares of Quotient stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $10.49, for a total value of $89,332.84. Following the sale, the chief financial officer now directly owns 21,497 shares of the company’s stock, valued at approximately $225,503.53. The disclosure for this sale can be found here.

Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.